#USA #Philadelphia #Type 1 Diabetes #Research Awards #Breakthrough T1D

Breakthrough T1D Celebrates Research Award Winners

On October 27, 2026, Breakthrough T1D, a preeminent global organization in Type 1 Diabetes (T1D) advocacy and research, hosted an event in Philadelphia to honor four exceptional leaders in T1D research. The awards presented recognize individuals whose transformative work has significantly advanced the organization's mission to expedite research towards potential cures for T1D and improve the quality of life for those affected by this condition.

Award Winners

The award recipients included:

• - Carla Greenbaum, M.D. - Recipient of the George Eisenbarth Award for Type 1 Diabetes Prevention
• - William Tamborlane, M.D. - Recipient of the Breakthrough T1D David Rumbough Award
• - Peter Thompson, Ph.D. - Recipient of the Dr. Robert Goldstein Award
• - Roy Beck, M.D., Ph.D. - Recipient of the Mary Tyler Moore and S. Robert Levine, M.D., Excellence in Clinical Research Award

Dr. Sanjoy Dutta, Chief Scientific Officer of Breakthrough T1D, emphasized the importance of these awards in acknowledging the remarkable contributions made by these individuals. He noted, "This group of researchers has played a pivotal role in significant scientific breakthroughs that have enhanced our understanding of T1D and fostered innovative technologies and therapies that have changed the course of the disease for millions globally."

Detailed Overview of Each Award

George Eisenbarth Award for Type 1 Diabetes Prevention

Named after a leading researcher, this award honors groundbreaking contributions to the prevention of T1D. Dr. Carla Greenbaum has been a front-runner in T1D research, conducting seminal studies on the predictive capabilities of autoantibodies in T1D and leading trials designed to halt its progression. Her extensive career spans several decades, and her current leadership role involves directing initiatives to develop therapeutic interventions for T1D.

Breakthrough T1D David Rumbough Award

This award acknowledges exceptional achievements that have dramatically propelled Breakthrough T1D's mission. Dr. William Tamborlane is famed for his innovations in pediatric endocrinology and diabetes research, particularly his work on insulin pumps that have significantly altered T1D management. His research has profoundly influenced clinical approaches and guidelines in treating T1D, underscoring the importance of reaching glycemic targets to prevent complications.

Dr. Robert Goldstein Award

Honoring the late Dr. Robert Goldstein for his instrumental role in advancing T1D research, this award recognizes promising early-career researchers. Dr. Peter Thompson’s groundbreaking research at the University of Manitoba focuses on cellular senescence—a factor in beta-cell dysfunction in T1D—offering insights into potential therapeutic avenues.

Excellence in Clinical Research Award

Named after Mary Tyler Moore, this accolade acknowledges exceptional contributions to T1D research. Dr. Roy Beck, with over three decades of experience in directing clinical trials, has substantially advanced the field through his leadership at the JAEB Center for Health Research. His involvement in numerous pivotal studies has enriched the understanding and management of T1D.

Conclusion

The awards ceremony symbolizes Breakthrough T1D’s commitment to acknowledging the relentless efforts of researchers aiming to combat Type 1 Diabetes. The organization's continual investment in promising research and its advocacy efforts play a crucial role in driving meaningful progress for individuals impacted by T1D.

About Breakthrough T1D

Formerly known as JDRF, Breakthrough T1D is the leading global organization focused on Type 1 Diabetes research and advocacy, dedicated to improving daily life for those with T1D while striving for cures. T1D affects millions worldwide and is characterized by the body's inability to produce insulin due to autoimmune destruction of pancreatic beta cells. Through its initiatives, Breakthrough T1D aims to foster collaboration among researchers, clinicians, and policymakers to address the challenges faced by the T1D community.